Figure 3.
MV130 shows key features of trained immunity
(A) Graphical outline: wild-type C57BL/6 and Rag1−/− mice were treated with MV130 (109 bacteria/mL) or excipient at day −7 and day −4, followed by intravenous infection with 3 × 105 (B) or 1.5 × 105 (C) C. albicans at day 0.
(B and C) Survival of wild-type C57BL/6 (B) and Rag1−/− (C) mice in two pooled independent experiments with n = 19 per group (B) and with n = 20 for excipient-treated and n = 19 for MV130-treated (C) mice. Survival curves were compared with log rank (Mantel-Cox) test. ∗∗p < 0.01.
(D) Graphical outline of the effect of in vivo inhibition with metformin (or not) in mice pretreated with MV130 (109 bacteria/mL) or excipient and subsequently challenged with influenza A virus (2 × 103 PFU/mouse = 2 × LD50).
(E and F) Weight loss (E) and survival (F) of mice following the treatments indicated in (D). Results from a pool of two independent experiments are shown, with n = 13 for excipient, n = 11 for MV130, n = 12 for excipient + metformin, and n = 13 for MV130 + metformin treated mice. Weights were compared using a two-way ANOVA test comparing MV130 and metformin + MV130 groups. Survival curves were compared with log rank (Mantel-Cox) test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
(G) Graphical outline for data in (H) and (I).
(H and I) Weight loss (H) and survival (I) of mice following 2 weeks of treatment with MV130/excipient as shown in (G). Results from a pool of two independent experiments are shown (n = 20 in excipient group and 18 in MV130 group). (E and H) data are shown as mean ± SEM. Weights were compared using a two-way ANOVA test comparing MV130 and excipient groups. Survival curves were compared with log rank (Mantel-Cox) test. ∗∗p < 0.01; ∗∗∗p < 0.001.